Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension

Nishio, Shinichiro; Watanabe, Hiroshi; Kosuge, Kazuhiro; Uchida, Shinya; Hayashi, Hideharu; Ohashi, Kyoichi

doi:10.1291/hypres.28.223

Cited by 72 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, amlodipine had no effect on any pharmacokinetic parameters of warfarin given intravenously, implying that coadministration of amlodipine could inhibit CYP3A4-mediated metabolism of warfarin, resulting in reducing intestinal or hepatic fi rst-pass metabolism (Abernethy et al, 1991;Stoysich et al, 1996;Wallin et al, 2002). These results were consistent with the results reported by Nishio et al (2005).…”

Section: Discussionsupporting

confidence: 78%

“…Although structurally related to other dihydropyridine derivatives, amlodipine displays signifi cantly different pharmacokinetic characteristics (Meredith et al, 1992). Amlodipine is a substrate of cytochrome P450 (CYP) 3A subfamily, specifi cally CYP3A4 (Nishio et al, 2005;Kim et al, 2009). In addition, amlodipine is also a P-glycoprotein (P-gp) substrate (Darvari and Boroujerdi, 2004;Harmsze et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats

Choi¹,

Piao²,

Choi³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats

Choi¹,

Piao²,

Choi³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

“…This reduced side effect coupled with reduced dose frequency overcome compliance problems with patients, and eventually provides satisfactory clinical management of any disease involved (Wikstrand et al, 2003;Löbenberg et al, 2005). Like other statins, SV has many commonly reported adverse reactions including upper respiratory tract infections, headache, abdominal pain, constipation, and nausea (Duggan et al, 1989;Bradford et al, 1991;Nishio et al, 2005). One of the important adverse effects of simvastatin and the class in general is myopathy or its more severe form rhabdomyolysis.…”

Section: Discussionmentioning

confidence: 99%

“…

a These two authors equally contributed to this work.Received Oct 1, 2010 Revised Nov 1, 2010 (Duggan et al, 1989;Bradford et al, 1991;Nishio et al, 2005). It was also reported that higher incidences of adverse events are associated with higher drug concentrations of statins and the most serious adverse events associated with them are hepatotoxicity and myotoxicity (Duggan et al, 1989;Vickers et al, 1990a;Bradford et al, 1991;McClelland et al, 1991).

…”

mentioning

confidence: 99%

Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models

Shanmugam¹,

Ryu²,

Yoo³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

a These two authors equally contributed to this work.Received Oct 1, 2010 Revised Nov 1, 2010 (Duggan et al., 1989;Bradford et al., 1991;Nishio et al., 2005). It was also reported that higher incidences of adverse events are associated with higher drug concentrations of statins and the most serious adverse events associated with them are hepatotoxicity and myotoxicity (Duggan et al., 1989;Vickers et al., 1990a;Bradford et al., 1991;McClelland et al., 1991). Since, SA has the similar mechanism of action like other statins, higher peak concentrations of SA would be expected to be related with incidence of adverse events. Therefore, formulations of SA with reduced side effects and constant pharmacological activity are of interest.It was reported that lovastatin IR given as 20 mg twice daily produced a signifi cantly greater reduction in LDL cholesterol

show abstract

“…sore throat, fever), or check differential white blood cell before adding allopurinol, then every 2 weeks during the first 3 months of treatment, and periodically [16]. AUC of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors was significantly increased by amlodipine [17].…”

Section: Drug Use Without Indication Was the Second Most Cause Of Drpmentioning

confidence: 99%

A Study of Drug Related Problem in Urologic Patients: a Cohort Prospective Study

Faizah

Diniya

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Drug Related problems (DRPs) are the clinical domain of the pharmaceutical care practitioner. The purpose of identifying drug therapy problems is to help patients on achieving their goals of therapy and realizing the best possible outcomes from drug therapy. The purpose of this study was to determine the number of DRPs and to classify DRPs that occurred in post-operative patients from urology surgery ward. Methods:A 3-month prospective study was conducted by considering 62 hospitalized post-operative patients from urology surgery ward at the Teaching Hospital in Surabaya, East Java, Indonesia. Clinical pharmacists were involved in medical rounds to identify DRPs.Results: From 37 patients, 81 DRPs were identified in this study. About 20 patients were considered to have more than one DRP. The most common identified DRPs were overdosage (38%), drug use without indication (20%), improper drug (11%), drug interaction (10%), untreated indication (9%), adverse drug reaction (7%), failure to receive drug (4%), and subtherapeutic drugs (1%). The clinical pharmacists were involved in doing dose adjustment, monitoring, evaluating drug discontinuation, doing drug substitution and additional therapy, counseling to patients, increasing dose, and referring to prescriber. Conclusion:The most identified DRPs were overdosage, drug use without indication, and improper drug. Clinical pharmacist's intervention was required to identify, prevent, resolve DRPs, and assist patient on achieving their goals of therapy and improving their quality of life.

show abstract

Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension

Cited by 72 publications

References 30 publications

Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats

Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats

Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models

A Study of Drug Related Problem in Urologic Patients: a Cohort Prospective Study

Contact Info

Product

Resources

About